Hologic, Inc. $HOLX Shares Acquired by Swiss National Bank

Swiss National Bank lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 679,240 shares of the medical equipment provider’s stock after acquiring an additional 39,100 shares during the quarter. Swiss National Bank owned 0.31% of Hologic worth $44,259,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Empirical Finance LLC raised its stake in shares of Hologic by 4.0% during the 1st quarter. Empirical Finance LLC now owns 8,703 shares of the medical equipment provider’s stock worth $538,000 after buying an additional 334 shares during the period. LPL Financial LLC grew its position in shares of Hologic by 17.3% in the first quarter. LPL Financial LLC now owns 296,846 shares of the medical equipment provider’s stock valued at $18,336,000 after purchasing an additional 43,706 shares during the period. Mackenzie Financial Corp increased its stake in shares of Hologic by 7.2% during the first quarter. Mackenzie Financial Corp now owns 1,191,142 shares of the medical equipment provider’s stock worth $73,577,000 after purchasing an additional 80,468 shares in the last quarter. N.E.W. Advisory Services LLC acquired a new position in shares of Hologic during the 1st quarter worth about $107,000. Finally, Federated Hermes Inc. lifted its stake in Hologic by 5.5% in the 1st quarter. Federated Hermes Inc. now owns 8,148 shares of the medical equipment provider’s stock valued at $503,000 after buying an additional 428 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Up 0.5%

Shares of HOLX opened at $74.76 on Tuesday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The firm has a market cap of $16.66 billion, a P/E ratio of 31.02, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The company’s 50-day moving average price is $70.81 and its 200 day moving average price is $66.60. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $80.31.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same period last year, the business earned $1.01 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.88% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on HOLX. Argus increased their target price on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a report on Friday, September 19th. Morgan Stanley lifted their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. BTIG Research reiterated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. UBS Group increased their price target on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, July 31st. Finally, Evercore ISI set a $78.00 price objective on Hologic and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Five analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to data from MarketBeat, Hologic has an average rating of “Hold” and an average price target of $79.67.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.